Rabbit anti-Human RSK2 Polyclonal Antibody | anti-RSK2 antibody

RSK2 Antibody, Rabbit PAb, Antigen Affinity Purified

Cat. Num. AAA258270

• Reactivity: Human
• Applications: Immunoprecipitation, Western Blot
• Purity: Protein A & Antigen Affinity
• Synonyms: RSK2, Antibody; RSK2 Antibody, Rabbit PAb, Antigen Affinity Purified; Anti-RSK2 Antibody, Rabbit Polyclonal; ribosomal protein S6 kinase, 90kDa, polypeptide 3; Anti-CLS Antibody; Anti-HU-3 Antibody; Anti-ISPK-1 Antibody; Anti-MAPKAPK1B Antibody; Anti-MRX19 Antibody; Anti-p90-RSK2 Antibody; Anti-pp90RSK2 Antibody; Anti-RSK Antibody; Anti-RSK2 Antibody; Anti-S6K-alpha3 Antibody; anti-RSK2 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: Rabbit IgG
• Specificity: Human, Mouse; (Species predicted to react based on 100% sequence homology)
• Purity/Purification: Protein A & Antigen Affinity
• Form/Format: Liquid. 0.2um filtered solution in PBS

• Applicable Applications for anti-RSK2 antibody: IP (Immunoprecipitation), WB (Western Blot)
• Immunogen: A synthetic peptide corresponding to the C-terminus of the Human RSK2
• Conjugation: Unconjugated
• Preparation: Produced in rabbits immunized with a synthetic peptide corresponding to the C-terminus of the Human RSK2, and purified by antigen affinity chromatography.
• Preparation and Storage: This antibody can be stored at 2 degree C-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Preservative-Free. Avoid repeated freeze-thaw cycles.

IP (Immunoprecipitation)

(UTF1 was immunoprecipitated using:Lane A:0.5 mg HeLa Whole Cell LysateLane B:0.5 mg MCF7 Whole Cell LysateLane C:0.5 mg HepG2 Whole Cell LysateLane D:0.5 mg 293T Whole Cell Lysate4 uL anti- UTF1 rabbit polyclonal antibody and 60 ug of Immunomagnetic beads Protein A/G.Primary antibody:Anti- UTF1 rabbit polyclonal antibody, at 1:100 dilutionSecondary antibody:Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilutionDeveloped using the ECL technique.Performed under reducing conditions.Predicted band size: 84kDaObserved band size :95 kDa)

WB (Western Blot)

(Anti-RSK2 rabbit polyclonal antibody at 1:500 dilutionLane A: HeLa Whole Cell LysateLane B: MCF-7 Whole Cell LysateLane C: HepG2 Whole Cell LysateLane D: 293T Whole Cell LysateLysates/proteins at 30 ug per lane.SecondaryGoat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution.Developed using the ECL technique.Performed under reducing conditions.Predicted band size:84 kDa)

Related Product Information for anti-RSK2 antibody

Background: Coffin-Lowry syndrome (CLS) is a rare X-linked dominant disorder characterized by intellectual disability, craniofacial abnormalities, short stature, tapering fingers, hypotonia, and skeletal malformations. CLS is caused by mutations in the Ribosomal Protein S6 Kinase, 90 kDa, Polypeptide 3 (RPS6KA3) gene located at Xp22.12, which encodes Ribosomal S6 Kinase 2 (RSK2). This gene encodes for a growth factor-regulated serine/threonine-protein kinase, RSK2 (ribosomal S6 kinase 2), acting in the Ras-mitogen-activated protein kinase signaling pathway. Mutations in the RPS6KA3 gene are extremely heterogeneous and lead to premature termination of translation and/or to loss of phosphotransferase activity of the RSK2 protein. Screening for RSK2 mutations is essential in most cases to confirm the identification as well as for genetic counseling. This gene also affects nonsyndromic X-linked ID and nonsyndromic X-linked ID without bony abnormalities.

References

Nishimoto HK, et al. (2014) The historical coffin-lowry syndrome family revisited: Identification of two novel mutations of rps6ka3 in three male patients. Am J Med Genet A 164a (9): 2172-2179.
Matsumoto A, et al. (2013) An xp22.12 microduplication including rps6ka3 identified in a family with variably affected intellectual and behavioral disabilities. J Hum Genet 58 (11): 755-757.
Delaunoy JP, et al. (2006) Identification of novel mutations in the rsk2 gene (rps6ka3) in patients with coffin-lowry syndrome. Clin Genet 70 (2): 161-166.